KDM2B and familial dilated cardiomyopathy: In conclusion, this study serves to clarify the regulatory role of FBXL10 in diabetic heart inflammation, oxidative stress and apoptosis, demonstrating that FBXL10 could be a promising therapeutic approach for the treatment of DCM.